Lipophilic HMG-CoA Reductase Inhibitors Increase Myocardial Stunning in Dogs
Authors:
- Kazuo IchiharaKIKazuo Ichihara
- 1 February 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 35 (2) , 256-262
Abstract
Pretreatment of dogs with simvastatin, a lipophilic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, increases myocardial contractile dysfunction during reperfusion after ischemia (stunning), with reduction of tissue adenosine triphosphate (ATP). This was thought to be a consequence of prevention of ubiquinone biosynthesis by the lipophilic inhibitor in the myocardial cell. We examined whether other lipophilic HMG-CoA reductase inhibitors also influence myocardial stunning in dogs. Vehicle, atorvastatin (2 mg/kg/day), fluvastatin (4 mg/kg/day), or cerivastatin (40 μg/kg/day) was orally administered for 3 weeks. Hydrophilic pravastatin (4 mg/kg/day) also was given. After 3 weeks, pentobarbital-anesthetized dogs were subjected to 15-min left anterior descending coronary artery occlusion followed by 2-h reperfusion. Myocardial segment function was determined by sonomicrometry. Tissue levels of ATP were determined in 2-h reperfused hearts. All inhibitors significantly decreased serum cholesterol level. The three lipophilic inhibitors resulted in a worsening of segment function in the reperfused myocardium, as compared with the vehicle group. The levels of ATP in the atorvastatin, fluvastatin, and cerivastatin groups were significantly lower than that in the vehicle group. These results confirm that lipophilic HMG-CoA reductase inhibitors enhance myocardial stunning in association with ATP reduction after ischemia and reperfusion.Keywords
This publication has 24 references indexed in Scilit:
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Pregnancy and breast cancerThe Lancet, 1994
- Pravastatin, lipids, and major coronary eventsThe American Journal of Cardiology, 1994
- Influences of Pravastatin and Simvastatin, HMG-CoA Reductase Inhibitors, on Myocardial Stunning in DogsJournal of Cardiovascular Pharmacology, 1993
- Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factorsThe American Journal of Cardiology, 1993
- Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
- Regulation of the mevalonate pathwayNature, 1990
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal speciesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
- Absence of a cumulative deterioration of regional function during three repeated 5 or 15 minute coronary occlusions.Circulation, 1984